StockGuru Blog: Skinvisible Pharmaceuticals, Inc. (OTCBB:SKVI) and (OTCQB:SKVI) Feasibility Agreement with Major Pharmaceutical Company

Skinvisible, Inc. (OTCBB: SKVI)

Skinvisible Pharmaceuticals, Inc. (OTCBB:SKVI) and (OTCQB:SKVI) Feasibility Agreement with Major Pharmaceutical Company

SKINVISIBLE PHARMACEUTICALS, INC. has entered into a feasibility agreement with Novartis Pharma AG

Under the agreement Skinvisible will assess the technical feasibility of a topical formulation with an undisclosed compound utilizing its proprietary Invisicare® polymer delivery system. This formulation, if successful, would leverage Invisicare’s proprietary main benefits by providing controlled release of the proprietary active ingredient.

Invisicare® is a versatile delivery system. The polymers deliver the active ingredient and bind to the skin resisting both wash-off and perspiration.
A good analogy in understanding the way SKVI’s Invisicare® works is that the polymer delivery system is the envelope that carries the letter or the active ingredient provided by Novartis to the skin in a controlled release format.

Invisicare® offers the following key benefits:
• Displays superior skin adherence for extended time periods
• Non-occlusive yet resists water wash-off, respiration and perspiration
• Offers advantage of controlled and/or sustained time-release
• Highly compatible with a variety of actives and bases
• Easy to emulsify
• Formulates well as a cream, lotion, or spray viscosity
• Non-irritating emulsion dries quickly with no greasy after-feel
• Broad polymer selection to meet application requirements
• Offers “Life Cycle” management to core products with potential for new patent

The agreement includes the option for the two companies to enter into a future exclusive licensing agreement which would include both a licensing fee and royalties based on sales.

About Novartis

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group’s continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com .

Forward-Looking Statements: This release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending October 31, 2010).
Contact:

Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: info@skinvisible.com

StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru has covered SKVI before for compensation, however, today we are covering this release due to the recent activity in the stock and the significance of the news. StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010. The company paid us five thousand dollars per month in cash for the period one month. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold no shares and will not be receiving further compensation that is share related during this period. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Left Menu Icon
Right Menu Icon